Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
The Polyclinic
mi
from
Seattle, WA
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
The Polyclinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Axiom Research
mi
from
Apple Valley, CA
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Axiom Research
mi
from
Apple Valley, CA
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
QUEST Research Institute
mi
from
Farmington Hills, MI
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
QUEST Research Institute
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Jordan River Family Medicine
mi
from
South Jordan, UT
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Jordan River Family Medicine
mi
from
South Jordan, UT
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Catalina Research Institute, LLC
mi
from
Montclair, CA
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Catalina Research Institute, LLC
mi
from
Montclair, CA
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
mi
from
Ciudad Autonoma de Buenos Aires,
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated:  12/31/1969
Christie Clinic
mi
from
Champaign, IL
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Status: Enrolling
Updated: 12/31/1969
Christie Clinic
mi
from
Champaign, IL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Arizona Research Center
mi
from
Phoenix, AZ
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Arizona Research Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute, Encino
mi
from
Encino, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute, Encino
mi
from
Encino, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Fullerton Neurology and Headache Center
mi
from
Fullerton, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Fullerton Neurology and Headache Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute, Los Alamitos
mi
from
Los Alamitos, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute, Los Alamitos
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute, Newport Beach
mi
from
Newport Beach, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute, Newport Beach
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Anderson Clinical Research
mi
from
Redlands, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Anderson Clinical Research
mi
from
Redlands, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Advanced Neurosciences Research, LLC
mi
from
Fort Collins, CO
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Advanced Neurosciences Research, LLC
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Psychiatric Inst of Florida-Clinical Neuroscience Solutions
mi
from
Orlando, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Psychiatric Inst of Florida-Clinical Neuroscience Solutions
mi
from
Orlando, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Compass Research
mi
from
Oviedo, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Compass Research
mi
from
Oviedo, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Trials
mi
from
Boise, ID
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Trials
mi
from
Boise, ID
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Robbins Headache Clinic
mi
from
Riverwoods, IL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Robbins Headache Clinic
mi
from
Riverwoods, IL
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Phoenix Medical Research
mi
from
Prairie Village, KA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Clinvest
mi
from
Springfield, MO
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Clinvest
mi
from
Springfield, MO
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Dent Neurological Institute
mi
from
Amherst, NY
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Dent Neurological Institute
mi
from
Amherst, NY
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Island Neuro Associates,PC
mi
from
Plainview, NY
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Island Neuro Associates,PC
mi
from
Plainview, NY
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Healthcare Research Consultant
mi
from
Tulsa, OK
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Healthcare Research Consultant
mi
from
Tulsa, OK
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of South Carolina
mi
from
Charleston, SC
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials